Author

Ahmed Abulfathi

Post-Doctoral Research Associate, University of Florida - Cited by 213 - Clinical Pharmacology - Pharmacometrics - Infectious Diseases - Medicine

Biography

Dr. Ahmed Abulfathi is currently affiliated with the Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Dr. Ahmed Abulfathi expertise in Clinical Pharmacology
Title
Cited by
Year
Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis–a systematic review of global literature with focus on South Africa
T Kastien-Hilka, A Abulfathi, B Rosenkranz, B Bennett, M Schwenkglenks, ...Health and quality of life outcomes 14, 1-13, 2016201
86
2016
Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis
AA Abulfathi, EH Decloedt, EM Svensson, AH Diacon, P Donald, H ReuterClinical pharmacokinetics 58, 1103-1129, 2019201
64
2019
The pharmacokinetics of para‐aminosalicylic acid and its relationship to efficacy and intolerance
AA Abulfathi, PR Donald, K Adams, EM Svensson, AH Diacon, H ReuterBritish Journal of Clinical Pharmacology 86 (11), 2123-2132, 2020202
14
2020
Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: the COMRADE randomized, phase 2A clinical trial
V De Jager, N Gupte, S Nunes, GL Barnes, RC van Wijk, J Mostert, ...American journal of respiratory and critical care medicine 205 (10), 1228-1235, 2022202
13
2022
Evaluation of the effectiveness of dose individualization to achieve therapeutic vancomycin concentrations
AA Abulfathi, M Chirehwa, B Rosenkranz, EH DecloedtThe Journal of Clinical Pharmacology 58 (9), 1134-1139, 2018201
12
2018
Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018
T Du Toit, TM Esterhuizen, N Tiffin, AA Abulfathi, H Reuter, EH DecloedtBMC Infectious Diseases 20, 1-8, 2020202
6
2020
Antibiotic prescribing habits among primary healthcare workers in Northern Nigeria: a concern for patient safety in the era of global antimicrobial resistance
MM Manga, Y Mohammed, S Suleiman, A Fowotade, Z Yunusa-Kaltungo, ...PAMJ-One Health 5, 2021202
4
2021
Drug concentration at the site of disease in children with pulmonary tuberculosis
E Lopez-Varela, AA Abulfathi, N Strydom, P Goussard, AC van Wyk, ...Journal of Antimicrobial Chemotherapy 77 (6), 1710-1719, 2022202
3
2022
Pharmacokinetics of Para‐Aminosalicylic acid and its 2 major metabolites: a potential relationship to the development of gastrointestinal intolerance
KT Adams, PR Donald, AA Abulfathi, AH Diacon, MA Stander, H ReuterThe Journal of Clinical Pharmacology 60 (4), 489-494, 2020202
3
2020
Population pharmacokinetic and safety analysis of ropivacaine used for erector spinae plane blocks
ES Schwenk, E Lam, AA Abulfathi, S Schmidt, A Gebhart, SD Witzeling, ...Regional Anesthesia & Pain Medicine, 030
2
2023
New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians
JM Aguilar Diaz, AA Abulfathi, LH Te Brake, J van Ingen, S Kuipers, ...Respiration 10 (), 83-100, 030
2
2023
Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens
AA Abulfathi, P Assawasuwannakit, PR Donald, AH Diacon, H Reuter, ...European Journal of Clinical Pharmacology 76, 1557-1565, 000
2
2020
The population pharmacokinetics of meropenem in adult patients with rifampicin-sensitive pulmonary tuberculosis
AA Abulfathi, V de Jager, E van Brakel, H Reuter, N Gupte, N Vanker, ...Frontiers in Pharmacology 2, 63768, 20220
1
2021
Angio-oedema associated with colistin
AA Abulfathi, T Greyling, M Makiwane, M Esser, E DecloedtSouth African Medical Journal 06 (0), 990-99, 20620
1
2016

Referred From: https://scholar.google.com/citations?user=jhBwIAIAAAAJ&hl=en

Cited by
Citations 213
h-index 6
i10-index 5
Recommended Journals
Open Access Journals